Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CK1ε inhibitors(casein kinase 1 epsilon inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral T-Cell Lymphoma | Phase 3 | CN | 28 Jun 2024 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | CN | 29 Dec 2021 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | CN | 29 Dec 2021 | |
B-cell lymphoma recurrent | IND Approval | CN | 15 Dec 2023 | |
B-cell lymphoma refractory | IND Approval | CN | 15 Dec 2023 |
Phase 1 | 38 | (lkxtsbxfaa) = wgbpqrlisi abpqcpffcu (hibwiwqdko ) View more | - | 11 Dec 2023 |